US5948634A
(en)
*
|
1988-12-21 |
1999-09-07 |
The General Hospital Coporation |
Neural thread protein gene expression and detection of alzheimer's disease
|
US5859221A
(en)
*
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5623065A
(en)
*
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6005087A
(en)
*
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5670633A
(en)
*
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US5955589A
(en)
*
|
1991-12-24 |
1999-09-21 |
Isis Pharmaceuticals Inc. |
Gapped 2' modified oligonucleotides
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
AU650032B2
(en)
*
|
1990-06-19 |
1994-06-09 |
Gene Shears Pty. Limited |
Endonucleases
|
PL169576B1
(pl)
*
|
1990-10-12 |
1996-08-30 |
Max Planck Gesellschaft |
Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US6307040B1
(en)
|
1992-03-05 |
2001-10-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US5856455A
(en)
*
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
US6277603B1
(en)
|
1991-12-24 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
EP1044987B1
(de)
|
1991-12-24 |
2006-02-15 |
Isis Pharmaceuticals, Inc. |
Unterbrochene 2'-modifizierte Oligonukleotide
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
US6204027B1
(en)
*
|
1992-02-26 |
2001-03-20 |
University Of Massachusetts Worcester |
Ribozymes having 2′-O substituted nucleotides in the flanking sequences
|
US6469158B1
(en)
*
|
1992-05-14 |
2002-10-22 |
Ribozyme Pharmaceuticals, Incorporated |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5804683A
(en)
*
|
1992-05-14 |
1998-09-08 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA with alkylamine
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US20040054156A1
(en)
*
|
1992-05-14 |
2004-03-18 |
Kenneth Draper |
Method and reagent for inhibiting hepatitis B viral replication
|
US20040127446A1
(en)
*
|
1992-05-14 |
2004-07-01 |
Lawrence Blatt |
Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
|
US20030125270A1
(en)
*
|
2000-12-18 |
2003-07-03 |
Lawrence Blatt |
Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5686599A
(en)
*
|
1992-05-14 |
1997-11-11 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5652355A
(en)
*
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US5646042A
(en)
*
|
1992-08-26 |
1997-07-08 |
Ribozyme Pharmaceuticals, Inc. |
C-myb targeted ribozymes
|
US5891684A
(en)
*
|
1992-10-15 |
1999-04-06 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
NZ257484A
(en)
*
|
1992-11-03 |
1997-08-22 |
Gene Shears Pty Ltd |
Nucleotides active against tnf-alpha, treatment of viral diseases
|
US5864028A
(en)
*
|
1992-11-03 |
1999-01-26 |
Gene Shears Pty. Limited |
Degradation resistant mRNA derivatives linked to TNF-α ribozymes
|
GB9225427D0
(en)
*
|
1992-12-04 |
1993-01-27 |
Ribonetics Gmbh |
Oligonucleotides with rna cleavage activity
|
US5811300A
(en)
*
|
1992-12-07 |
1998-09-22 |
Ribozyme Pharmaceuticals, Inc. |
TNF-α ribozymes
|
US5658780A
(en)
|
1992-12-07 |
1997-08-19 |
Ribozyme Pharmaceuticals, Inc. |
Rel a targeted ribozymes
|
US5616488A
(en)
*
|
1992-12-07 |
1997-04-01 |
Ribozyme Pharmaceuticals, Inc. |
IL-5 targeted ribozymes
|
US5612215A
(en)
*
|
1992-12-07 |
1997-03-18 |
Ribozyme Pharmaceuticals, Inc. |
Stromelysin targeted ribozymes
|
US5837542A
(en)
*
|
1992-12-07 |
1998-11-17 |
Ribozyme Pharmaceuticals, Inc. |
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
|
US5817635A
(en)
*
|
1993-08-09 |
1998-10-06 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Modified ribozymes
|
WO1995006731A2
(en)
|
1993-09-02 |
1995-03-09 |
Ribozyme Pharmaceuticals, Inc. |
Non-nucleotide containing enzymatic nucleic acid
|
WO1995006764A2
(en)
*
|
1993-09-03 |
1995-03-09 |
Vpi Holdings Ltd. |
Oligonucleotides with rna cleavage activity
|
US5861288A
(en)
*
|
1993-10-18 |
1999-01-19 |
Ribozyme Pharmaceuticals, Inc. |
Catalytic DNA
|
JPH09504297A
(ja)
*
|
1993-10-27 |
1997-04-28 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
2′−アミドおよび2′−ペプチド修飾オリゴヌクレオチド
|
AU730347B2
(en)
*
|
1993-11-08 |
2001-03-08 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
AU687479B2
(en)
|
1993-11-08 |
1998-02-26 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
US6897016B1
(en)
|
1993-11-12 |
2005-05-24 |
The Regents Of The University Of Colorado |
Alteration of sequence of a target molecule
|
CA2183992A1
(en)
*
|
1994-02-23 |
1995-08-31 |
Dan T. Stinchcomb |
Method and reagent for inhibiting the expression of disease related genes
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US5902880A
(en)
*
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5631359A
(en)
*
|
1994-10-11 |
1997-05-20 |
Ribozyme Pharmaceuticals, Inc. |
Hairpin ribozymes
|
US5693532A
(en)
*
|
1994-11-04 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
Respiratory syncytial virus ribozymes
|
EP1260586A3
(de)
*
|
1994-02-23 |
2004-04-28 |
Ribozyme Pharmaceuticals, Inc. |
Verfahren und Verbindung zur Verringerung des Expression von Genen, die in Verbindung mit Krankheiten stehen
|
US5627053A
(en)
*
|
1994-03-29 |
1997-05-06 |
Ribozyme Pharmaceuticals, Inc. |
2'deoxy-2'-alkylnucleotide containing nucleic acid
|
US6103890A
(en)
*
|
1994-05-18 |
2000-08-15 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids that cleave C-fos
|
US5633133A
(en)
*
|
1994-07-14 |
1997-05-27 |
Long; David M. |
Ligation with hammerhead ribozymes
|
US6146886A
(en)
*
|
1994-08-19 |
2000-11-14 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5599706A
(en)
*
|
1994-09-23 |
1997-02-04 |
Stinchcomb; Dan T. |
Ribozymes targeted to apo(a) mRNA
|
US5700923A
(en)
*
|
1994-09-29 |
1997-12-23 |
Hybridon, Inc. |
Finderons and methods of their preparation and use
|
US5672501A
(en)
*
|
1994-12-23 |
1997-09-30 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
US5716824A
(en)
*
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
US5545729A
(en)
*
|
1994-12-22 |
1996-08-13 |
Hybridon, Inc. |
Stabilized ribozyme analogs
|
US5705388A
(en)
*
|
1994-12-23 |
1998-01-06 |
Ribozyme Pharmaceuticals, Inc. |
CETP Ribozymes
|
US6017887A
(en)
*
|
1995-01-06 |
2000-01-25 |
Sibia Neurosciences, Inc. |
Peptide, peptide analog and amino acid analog protease inhibitors
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
US5663064A
(en)
*
|
1995-01-13 |
1997-09-02 |
University Of Vermont |
Ribozymes with RNA protein binding site
|
US5877021A
(en)
|
1995-07-07 |
1999-03-02 |
Ribozyme Pharmaceuticals, Inc. |
B7-1 targeted ribozymes
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
US7034009B2
(en)
|
1995-10-26 |
2006-04-25 |
Sirna Therapeutics, Inc. |
Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
US20040102389A1
(en)
*
|
1995-10-26 |
2004-05-27 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US20040220128A1
(en)
*
|
1995-10-26 |
2004-11-04 |
Sirna Therapeutics, Inc. |
Nucleic acid based modulation of female reproductive diseases and conditions
|
ATE213019T1
(de)
*
|
1995-11-14 |
2002-02-15 |
Vimrx Holdings Ltd |
Chimäre oligomere mit einer rns- spaltungsaktivität
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
DE69729145T2
(de)
*
|
1996-05-24 |
2005-06-09 |
Aventis Pharma Deutschland Gmbh |
Reagenz und Verfahren zur Inhibierung der N-RAS Expression
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US5807743A
(en)
*
|
1996-12-03 |
1998-09-15 |
Ribozyme Pharmaceuticals, Inc. |
Interleukin-2 receptor gamma-chain ribozymes
|
EP0946736B1
(de)
*
|
1996-12-13 |
2003-10-29 |
Chiron Corporation |
Verfahren zur expression von heterologen proteinen in hefe
|
AU724627B2
(en)
*
|
1996-12-19 |
2000-09-28 |
Yale University |
Bioreactive allosteric polynucleotides
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
US20030186909A1
(en)
*
|
1997-01-27 |
2003-10-02 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
US6057156A
(en)
|
1997-01-31 |
2000-05-02 |
Robozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
US6159951A
(en)
|
1997-02-13 |
2000-12-12 |
Ribozyme Pharmaceuticals Inc. |
2'-O-amino-containing nucleoside analogs and polynucleotides
|
US7226730B1
(en)
|
1997-02-26 |
2007-06-05 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
|
CA2282729A1
(en)
|
1997-02-26 |
1998-09-03 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
|
US6251666B1
(en)
|
1997-03-31 |
2001-06-26 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid catalysts comprising L-nucleotide analogs
|
US6280936B1
(en)
|
1997-06-09 |
2001-08-28 |
Ribozyme Pharmaceuticals, Inc. |
Method for screening nucleic acid catalysts
|
US6548657B1
(en)
|
1997-06-09 |
2003-04-15 |
Ribozyme Pharmaceuticals, Inc. |
Method for screening nucleic acid catalysts
|
US6183959B1
(en)
|
1997-07-03 |
2001-02-06 |
Ribozyme Pharmaceuticals, Inc. |
Method for target site selection and discovery
|
US6316612B1
(en)
|
1997-08-22 |
2001-11-13 |
Ribozyme Pharmaceuticals, Inc. |
Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
|
EP1030913A2
(de)
*
|
1997-09-22 |
2000-08-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Katalytische nukleinsäuren mit endonuklease aktivität
|
US6656731B1
(en)
|
1997-09-22 |
2003-12-02 |
Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Nucleic acid catalysts with endonuclease activity
|
US6054576A
(en)
|
1997-10-02 |
2000-04-25 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA
|
US6482932B1
(en)
*
|
1997-11-05 |
2002-11-19 |
Ribozyme Pharmaceuticals, Incorporated |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
US6127535A
(en)
*
|
1997-11-05 |
2000-10-03 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
WO1999054459A2
(en)
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
CA2230203A1
(en)
|
1998-04-29 |
1999-10-29 |
Universite De Sherbrooke |
Delta ribozyme for rna cleavage
|
JP2002525077A
(ja)
*
|
1998-08-26 |
2002-08-13 |
サウス、アラバマ、メディカル、サイエンス、ファウンデーション |
T型カルシウムチャンネル
|
US20030125269A1
(en)
*
|
1998-08-26 |
2003-07-03 |
Ming Li |
T-type calcium channel
|
US6175004B1
(en)
*
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
IL126732A0
(en)
*
|
1998-10-23 |
1999-08-17 |
Intelligene Ltd |
Pro drug
|
US6995259B1
(en)
*
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
WO2000064920A1
(en)
|
1999-04-27 |
2000-11-02 |
The Trustees Of The University Of Pennsylvania |
Compositions, methods, and kits relating to resistin
|
WO2000066780A2
(en)
|
1999-04-30 |
2000-11-09 |
University Of Florida |
Adeno-associated virus-delivered ribozyme compositions and methods of use
|
US6617442B1
(en)
*
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
US6831171B2
(en)
|
2000-02-08 |
2004-12-14 |
Yale University |
Nucleic acid catalysts with endonuclease activity
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
WO2005041859A2
(en)
|
2003-04-30 |
2005-05-12 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery.
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US7833992B2
(en)
*
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
WO2002081628A2
(en)
*
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
JP2003525037A
(ja)
*
|
2000-02-11 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Cd20およびnogo遺伝子発現の調節および診断のための方法および試薬
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US6846486B1
(en)
|
2000-02-24 |
2005-01-25 |
Advanced Biotherapy Concepts, Inc. |
Method of treating allergy by administering an anti-histamine antibody
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20030065155A1
(en)
*
|
2000-03-06 |
2003-04-03 |
Nassim Usman |
Nucleic acid sensor molecules
|
US20040009510A1
(en)
*
|
2000-03-06 |
2004-01-15 |
Scott Seiwert |
Allosteric nucleic acid sensor molecules
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US20080032942A1
(en)
*
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
DK2813582T3
(en)
*
|
2000-12-01 |
2017-07-31 |
Max-Planck-Gesellschaft Zur Förderung Der Wss E V |
Small RNA molecules that mediate RNA interference
|
US7049059B2
(en)
*
|
2000-12-01 |
2006-05-23 |
Response Genetics, Inc. |
Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
|
CA2441071C
(en)
|
2001-03-14 |
2010-06-22 |
Myriad Genetics, Inc. |
Tsg101-gag interaction and use thereof
|
JP2004532022A
(ja)
*
|
2001-03-26 |
2004-10-21 |
サーナ・セラピューティクス・インコーポレイテッド |
B型肝炎ウイルスおよびc型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
|
CA2443050A1
(en)
|
2001-03-30 |
2002-10-10 |
Philadelphia Health And Education Corporation |
Immunomodulation and effect on cell processes relating to serotonin family receptors
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
WO2002097114A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20030170891A1
(en)
*
|
2001-06-06 |
2003-09-11 |
Mcswiggen James A. |
RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
EP3231445A1
(de)
|
2001-05-18 |
2017-10-18 |
Sirna Therapeutics, Inc. |
Konjugate und zusammensetzungen zur zellulären verabreichung
|
US20030140362A1
(en)
*
|
2001-06-08 |
2003-07-24 |
Dennis Macejak |
In vivo models for screening inhibitors of hepatitis B virus
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
AU2002313699A1
(en)
*
|
2001-07-20 |
2003-03-03 |
Ribozyme Pharmacuticals, Inc. |
Enzymatic nucleic acid peptide conjugates
|
WO2003057709A2
(en)
*
|
2001-10-19 |
2003-07-17 |
Sirna Therapeutics, Inc |
Method and reagent for the detection of proteins and peptides
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
AU2002357240A1
(en)
*
|
2001-12-14 |
2003-06-30 |
Yale University |
Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
|
CA2476755C
(en)
|
2001-12-17 |
2014-08-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
US20050042632A1
(en)
*
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
US7071311B2
(en)
*
|
2002-02-13 |
2006-07-04 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for 2′-C-allyl nucleic acids
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20030195164A1
(en)
*
|
2002-04-16 |
2003-10-16 |
Veli-Matti Kahari |
Novel ribozyme and its use
|
US20040018520A1
(en)
*
|
2002-04-22 |
2004-01-29 |
James Thompson |
Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
|
US20030224435A1
(en)
*
|
2002-05-16 |
2003-12-04 |
Scott Seiwert |
Detection of abused substances and their metabolites using nucleic acid sensor molecules
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
US6989442B2
(en)
|
2002-07-12 |
2006-01-24 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
AU2003261264B2
(en)
*
|
2002-07-25 |
2008-12-11 |
Archemix Corp. |
Regulated aptamer therapeutics
|
EP1857547B2
(de)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Weitere neue Formen von interferierenden RNA-Molekülen
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US9303262B2
(en)
|
2002-09-17 |
2016-04-05 |
Archemix Llc |
Methods for identifying aptamer regulators
|
EP1546344A4
(de)
*
|
2002-09-18 |
2007-10-03 |
Isis Pharmaceuticals Inc |
Effiziente produktion von ziel-rnas mittels einzel- und doppelsträngiger oligomerverbindungen
|
EP1556402B1
(de)
|
2002-09-25 |
2011-06-22 |
University of Massachusetts |
Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
CA2504633A1
(en)
*
|
2002-11-21 |
2004-06-10 |
Archemix Corporation |
Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
WO2004050899A2
(en)
*
|
2002-12-03 |
2004-06-17 |
Archemix Corporation |
Method for in vitro selection of 2’-substituted nucleic acids
|
US20050037394A1
(en)
*
|
2002-12-03 |
2005-02-17 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
US20040209353A1
(en)
*
|
2002-12-12 |
2004-10-21 |
Chiron Corporation |
Biological sample storage device and method for biological sample contamination testing
|
US20040231231A1
(en)
*
|
2002-12-20 |
2004-11-25 |
Cataldo Dominic A. |
Use of colloidal clays for sustained release of active ingredients
|
US20030232400A1
(en)
*
|
2002-12-20 |
2003-12-18 |
Susan Radka |
Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
|
US20050085435A1
(en)
*
|
2003-01-02 |
2005-04-21 |
Niles Edward G. |
Novel inhibitors of poxvirus replication
|
US8088737B2
(en)
|
2003-04-04 |
2012-01-03 |
Incyte Corporation |
Compositions, methods and kits relating to Her-2 cleavage
|
EP1620112A4
(de)
*
|
2003-04-17 |
2007-04-25 |
Univ Columbia |
Desmoglein 4 ist ein neues gen, das am haarwachstum beteiligt ist
|
AU2004232848A1
(en)
|
2003-04-21 |
2004-11-04 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US20050250106A1
(en)
*
|
2003-04-24 |
2005-11-10 |
David Epstein |
Gene knock-down by intracellular expression of aptamers
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
PT1727567E
(pt)
|
2004-02-12 |
2013-10-14 |
Archemix Llc |
Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
|
US20070066550A1
(en)
*
|
2004-03-05 |
2007-03-22 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
US20080214489A1
(en)
*
|
2004-04-19 |
2008-09-04 |
Anthony Dominic Keefe |
Aptamer-mediated intracellular delivery of oligonucleotides
|
EP1747022A4
(de)
|
2004-04-23 |
2010-03-31 |
Univ Columbia |
Hemmung von haarloser protein mrna
|
US7579450B2
(en)
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
US20060040882A1
(en)
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
CN101437834B
(zh)
|
2004-07-19 |
2012-06-06 |
贝勒医学院 |
细胞因子信号转导调节剂的调节和用于免疫治疗的应用
|
AU2005272920B2
(en)
|
2004-08-10 |
2011-05-12 |
Institute For Multiple Myeloma And Bone Cancer Research |
Methods of regulating differentiation and treating of multiple myeloma
|
EP1789096A4
(de)
|
2004-09-07 |
2009-07-08 |
Archemix Corp |
Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
|
JP2008512097A
(ja)
|
2004-09-07 |
2008-04-24 |
アーケミックス コーポレイション |
アプタマー医薬品化学
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP2436391A3
(de)
|
2004-11-02 |
2012-07-04 |
Archemix LLC |
Stabilisierte Aptamere für einen aus Plättchen gewonnenen Wachstumsfaktor und ihre Verwendung als Krebstherapiemittel
|
WO2006066074A2
(en)
|
2004-12-16 |
2006-06-22 |
The Regents Of The University Of California |
Lung-targeted drugs
|
EP1863828A4
(de)
*
|
2005-03-07 |
2010-10-13 |
Archemix Corp |
Stabilisierte aptamere für psma und ihre verwendung als prostatakrebstherapeutika
|
ATE541928T1
(de)
|
2005-03-31 |
2012-02-15 |
Calando Pharmaceuticals Inc |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
US7868159B2
(en)
|
2005-06-23 |
2011-01-11 |
Baylor College Of Medicine |
Modulation of negative immune regulators and applications for immunotherapy
|
WO2007002904A2
(en)
|
2005-06-28 |
2007-01-04 |
Medtronic, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
CA2613442C
(en)
|
2005-06-30 |
2016-08-23 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
FI20055712A0
(fi)
*
|
2005-12-29 |
2005-12-29 |
Wallac Oy |
Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit
|
PT1981902E
(pt)
|
2006-01-27 |
2015-11-02 |
Biogen Ma Inc |
Antagonistas dos recetores nogo
|
US7922000B2
(en)
*
|
2006-02-15 |
2011-04-12 |
Miraial Co., Ltd. |
Thin plate container with a stack of removable loading trays
|
WO2007103549A2
(en)
|
2006-03-08 |
2007-09-13 |
Archemix Corp. |
Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
|
ES2544861T3
(es)
|
2006-03-31 |
2015-09-04 |
Alnylam Pharmaceuticals Inc. |
Composiciones y métodos para inhibir la expresión del gen Eg5
|
EP2010226B1
(de)
|
2006-04-07 |
2014-01-15 |
The Research Foundation of State University of New York |
Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
|
US8158782B2
(en)
*
|
2006-05-05 |
2012-04-17 |
Wallac Oy |
Biomolecule labeling reactants based on azacycloalkanes and conjugates derived thereof
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2471815B1
(de)
|
2006-07-11 |
2016-03-30 |
University Of Medicine And Dentistry Of New Jersey |
Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
|
US9505821B2
(en)
|
2006-10-03 |
2016-11-29 |
Rutgers, The State University Of New Jersey |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
WO2008067040A2
(en)
|
2006-10-06 |
2008-06-05 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US20100062436A1
(en)
|
2006-10-31 |
2010-03-11 |
Noxxon Pharma Ag |
Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US8808747B2
(en)
*
|
2007-04-17 |
2014-08-19 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
WO2008134077A1
(en)
*
|
2007-04-30 |
2008-11-06 |
Archemix Corp. |
Metabolic profile directed aptamer medicinal chemistry
|
EP2157982B1
(de)
|
2007-05-04 |
2014-12-17 |
Marina Biotech, Inc. |
Aminosäurelipide und ihre verwendungen
|
EP3351270A1
(de)
|
2007-05-23 |
2018-07-25 |
The Trustees of the University of Pennsylvania |
Gezielte träger zur intrazellulären arzneimittelabgabe
|
US8183221B2
(en)
|
2007-09-05 |
2012-05-22 |
Medtronic, Inc. |
Suppression of SCN9A gene expression and/or function for the treatment of pain
|
AR068542A1
(es)
*
|
2007-09-24 |
2009-11-18 |
Performance Plants Inc |
Plantas que tienen biomasa aumentada
|
US8324369B2
(en)
|
2007-11-30 |
2012-12-04 |
Baylor College Of Medicine |
Dendritic cell vaccine compositions and uses of same
|
EP4074344A1
(de)
|
2007-12-04 |
2022-10-19 |
Arbutus Biopharma Corporation |
Targeting von lipiden
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
WO2009123764A2
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of epas1 inhibitors
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
US20110229498A1
(en)
|
2008-05-08 |
2011-09-22 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
US20110212021A1
(en)
|
2008-05-30 |
2011-09-01 |
Slack Frank J |
Targeted oligonucleotide compositions for modifying gene expression
|
EP2633864A1
(de)
|
2008-07-25 |
2013-09-04 |
The Regents of the University of Colorado |
Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
|
EP2334692B1
(de)
*
|
2008-09-05 |
2016-04-13 |
The Royal Institution for the Advancement of Learning/McGill University |
Rna-monomere mit o-acetal-levulinylestergruppen und ihre verwendung für rna-mikroarrays
|
EP2341924A4
(de)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
Verfahren zur behandlung von hepatitis-c-virusinfektionen
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
US20100112042A1
(en)
|
2008-10-16 |
2010-05-06 |
Mdrna, Inc. |
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
|
ES2631507T3
(es)
|
2008-10-29 |
2017-08-31 |
China Synthetic Rubber Corporation |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
EP3699172A3
(de)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
US20100215660A1
(en)
|
2009-02-23 |
2010-08-26 |
Sarwar Hashmi |
Kruppel-like factors and fat regulation
|
JP6010458B2
(ja)
|
2009-04-03 |
2016-10-19 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. |
非対称二本鎖rnaによる特異的阻害のための、方法および組成物
|
EP2756845B1
(de)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
|
ES2573981T3
(es)
|
2009-04-10 |
2016-06-13 |
Association Institut De Myologie |
Oligonucleótidos antisentido de triciclo-ADN, composiciones, y métodos para el tratamiento de enfermedades
|
CN107252489A
(zh)
|
2009-04-13 |
2017-10-17 |
法国健康和医学研究院 |
Hpv颗粒及其用途
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
AU2010249881B2
(en)
|
2009-05-16 |
2015-01-22 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
|
US8158601B2
(en)
|
2009-06-10 |
2012-04-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulation
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
WO2011039646A2
(en)
|
2009-09-30 |
2011-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Papilloma virus -like particles for targeted gene delivery
|
US8450090B2
(en)
|
2009-10-06 |
2013-05-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for promoting fatty acid production in plants
|
US20120270930A1
(en)
|
2009-10-29 |
2012-10-25 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Methods and compositions for dysferlin exon-skipping
|
US8993741B2
(en)
|
2009-11-17 |
2015-03-31 |
The Trustees Of The University Of Pennsylvania |
SMNdelta7 degron: novel compositions and methods of use
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
KR20120125357A
(ko)
|
2010-02-10 |
2012-11-14 |
노파르티스 아게 |
근육 성장을 위한 방법 및 화합물
|
AU2011215753B2
(en)
|
2010-02-11 |
2015-09-03 |
Nanostring Technologies, Inc. |
Compositions and methods for the detection of small RNAs
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
EP2550361B1
(de)
|
2010-03-25 |
2017-02-08 |
The J. David Gladstone Institutes |
Zusammensetzungen und verfahren zur behandlung neurologischer störungen
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
ES2911185T3
(es)
|
2010-04-23 |
2022-05-18 |
Univ Florida |
Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
|
WO2011139710A1
(en)
|
2010-04-26 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds with conformationally restricted monomers and uses thereof
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
CA2804214C
(en)
|
2010-07-06 |
2022-04-12 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
|
WO2012006506A1
(en)
|
2010-07-09 |
2012-01-12 |
Massachusetts Institute Of Technology |
Metabolic gene, enzyme, and flux targets for cancer therapy
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
SG10201508118WA
(en)
|
2010-09-30 |
2015-11-27 |
Agency Science Tech & Res |
Methods and reagents for detection and treatment of esophageal metaplasia
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
US9072766B2
(en)
|
2010-11-18 |
2015-07-07 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
|
WO2012097093A2
(en)
|
2011-01-11 |
2012-07-19 |
Fate Therapeutics, Inc. |
Novel wnt compositions and therapeutic uses of such compositions
|
AU2012207606B2
(en)
|
2011-01-11 |
2017-02-23 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
EP2753631A1
(de)
|
2011-09-07 |
2014-07-16 |
Marina Biotech, Inc. |
Synthese und verwendung von nukleinsäureverbindungen mit konformationseingeschränkten monomeren
|
WO2013049328A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
PT2766393T
(pt)
|
2011-10-14 |
2018-10-15 |
Hoffmann La Roche |
Anticorpos anti-htra1 e métodos de utilização
|
US20150291999A1
(en)
|
2011-10-14 |
2015-10-15 |
Accugenomics, Inc. |
Nucleic acid amplification and use thereof
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
WO2013101645A1
(en)
|
2011-12-27 |
2013-07-04 |
The J. David Gladstone Institutes |
Compositions and methods for regulating glucose metabolism
|
US9700639B2
(en)
|
2012-02-07 |
2017-07-11 |
Aura Biosciences, Inc. |
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
|
KR20220045089A
(ko)
|
2012-02-24 |
2022-04-12 |
아뷰터스 바이오파마 코포레이션 |
트리알킬 양이온성 지질 및 그의 사용 방법
|
EP2855704A4
(de)
|
2012-05-25 |
2016-03-16 |
Accugenomics Inc |
Nukleinsäureamplifikation und anwendung davon
|
EP2866822B1
(de)
|
2012-07-05 |
2019-12-25 |
The Trustees Of The University Of Pennsylvania |
U1-snrnp als regulator der genexpression und modulator der onkogenität
|
KR101520383B1
(ko)
|
2012-08-02 |
2015-05-15 |
에이비온 주식회사 |
Hpv 감염과 관련된 암의 치료용 조성물
|
US9937205B2
(en)
|
2012-09-04 |
2018-04-10 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
|
US9958448B2
(en)
|
2012-10-23 |
2018-05-01 |
Caris Life Sciences Switzerland Holdings Gmbh |
Aptamers and uses thereof
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
US9939443B2
(en)
|
2012-12-19 |
2018-04-10 |
Caris Life Sciences Switzerland Holdings Gmbh |
Compositions and methods for aptamer screening
|
EP2964763B1
(de)
|
2013-03-08 |
2019-09-18 |
Yale University |
Zusammensetzungen und verfahren zur verminderung der hautpigmentierung
|
AU2014228321C1
(en)
|
2013-03-15 |
2019-07-11 |
The Regents Of The University Of California |
Acyclic nucleoside phosphonate diesters
|
DK3444350T3
(da)
|
2013-07-03 |
2022-02-07 |
Dicerna Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til specifik hæmning af alpha-1 antitrypsin ved dobbeltstrenget rna
|
EP3019200B1
(de)
|
2013-07-11 |
2022-03-23 |
Alnylam Pharmaceuticals, Inc. |
Oligonukleotid-ligandkonjugate und verfahren zu deren herstellung
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
BR112016004153A2
(pt)
|
2013-08-28 |
2019-09-17 |
Caris Life Sciences Switzerland Holdings Gmbh |
"método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
|
PT3046583T
(pt)
|
2013-09-18 |
2019-05-30 |
Aura Biosciences Inc |
Conjugados de partículas semelhantes a vírus para o tratamento de tumores
|
WO2015048531A1
(en)
|
2013-09-26 |
2015-04-02 |
Beth Israel Deaconess Medical Center, Inc. |
Inhibition of sgk1 in the treatment of heart conditions
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
US9365610B2
(en)
|
2013-11-18 |
2016-06-14 |
Arcturus Therapeutics, Inc. |
Asymmetric ionizable cationic lipid for RNA delivery
|
CA2930602C
(en)
|
2013-11-18 |
2019-05-28 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for rna delivery
|
AR093574A1
(es)
|
2013-11-21 |
2015-06-10 |
Consejo Nac De Investig Cientificas Y Tecn (Conicet) |
Aptameros contra la proteina basica de mielina como agentes neuroprotectores
|
CN113151180A
(zh)
|
2013-12-02 |
2021-07-23 |
菲奥医药公司 |
癌症的免疫治疗
|
ES2936812T3
(es)
|
2013-12-20 |
2023-03-22 |
Acetylon Pharmaceuticals Inc |
Biomarcadores de histona desacetilasa 6 (HDAC6) en mieloma múltiple
|
LT3581654T
(lt)
|
2013-12-27 |
2021-06-25 |
Dicerna Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti glikolato oksidazės (hao1) specifinei inhibicijai dvigrande rnr
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
WO2016004055A1
(en)
|
2014-07-03 |
2016-01-07 |
Yale University |
Dickkopf2 (Dkk2) Inhibition Suppresses Tumor Formation
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
HRP20220651T1
(hr)
|
2014-09-15 |
2022-08-19 |
The Regents Of The University Of California |
Nukleotidni analozi
|
US10351854B2
(en)
|
2014-10-10 |
2019-07-16 |
Dicerna Pharmaceuticals, Inc. |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
WO2016061131A1
(en)
|
2014-10-14 |
2016-04-21 |
The J. David Gladstone Institutes |
Compositions and methods for reactivating latent immunodeficiency virus
|
LT3221293T
(lt)
|
2014-11-18 |
2023-03-27 |
Arcturus Therapeutics, Inc. |
Jonizuojamas katijoninis lipidas, skirtas rnr pristatymui
|
WO2016081796A1
(en)
|
2014-11-21 |
2016-05-26 |
Yale University |
Compositions and methods for modulating salm5 and hvem
|
ES2747842T3
(es)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de doble hebra modificados por ligando
|
AU2015364282B2
(en)
|
2014-12-18 |
2021-04-15 |
Integrated Dna Technologies, Inc. |
CRISPR-based compositions and methods of use
|
MA41629A
(fr)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
|
WO2016145128A1
(en)
|
2015-03-09 |
2016-09-15 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
US10590425B2
(en)
|
2015-06-29 |
2020-03-17 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
EP3331536A4
(de)
|
2015-08-03 |
2019-03-27 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
|
MX2018005468A
(es)
|
2015-10-30 |
2018-11-09 |
The Us Secretary Department Of Health And Man Services |
Terapia dirigida contra el cáncer.
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
US10731166B2
(en)
|
2016-03-18 |
2020-08-04 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45468A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques myc et utilisations
|
MA45471A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
WO2017205686A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
US20190309274A1
(en)
|
2016-08-16 |
2019-10-10 |
Bluebird Bio, Inc. |
Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
|
WO2018039333A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
MX2019002725A
(es)
|
2016-09-08 |
2019-05-27 |
Bluebird Bio Inc |
Variantes de endonucleasas de asentamiento pd-1, composiciones y metodos de uso.
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
WO2018068053A2
(en)
|
2016-10-07 |
2018-04-12 |
Integrated Dna Technologies, Inc. |
S. pyogenes cas9 mutant genes and polypeptides encoded by same
|
EP4353822A2
(de)
|
2016-11-17 |
2024-04-17 |
2seventy bio, Inc. |
Tgf-beta-signalwandler
|
AU2017364084A1
(en)
|
2016-11-22 |
2019-05-16 |
Integrated Dna Technologies, Inc. |
CRISPR/Cpf1 systems and methods
|
US11293022B2
(en)
|
2016-12-12 |
2022-04-05 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
WO2018119163A1
(en)
|
2016-12-21 |
2018-06-28 |
Payne Joseph E |
Ionizable cationic lipid for rna delivery
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
CN110381980A
(zh)
|
2017-01-06 |
2019-10-25 |
艾维迪提生物科学有限责任公司 |
核酸-多肽组合物以及诱导外显子跳读的方法
|
US11499149B2
(en)
|
2017-02-15 |
2022-11-15 |
2Seventy Bio, Inc. |
Donor repair templates multiplex genome editing
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
US11306312B2
(en)
|
2017-09-01 |
2022-04-19 |
Thomas Jefferson University |
Compositions and methods for MYC messenger RNA inhibitors
|
US11110180B2
(en)
|
2017-10-04 |
2021-09-07 |
Avidity Biosciences Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
USES OF BASIC EDITORS ADENOSINE
|
SG11202005022YA
(en)
|
2017-12-06 |
2020-06-29 |
Avidity Biosciences Inc |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
WO2019136456A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
CN112424352A
(zh)
|
2018-05-11 |
2021-02-26 |
阿尔法阿诺麦里克公司 |
包括7′-5′-α-异头双环糖核苷的寡核苷酸缀合物
|
HUE064076T2
(hu)
|
2018-12-06 |
2024-02-28 |
Arcturus Therapeutics Inc |
Készítmények és módszerek az ornitin-transzkarbamiláz hiányának kezelésére
|
WO2020191239A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
EP3980436A4
(de)
|
2019-06-06 |
2023-12-20 |
Avidity Biosciences, Inc. |
Nukleinsäurepolypeptidzusammensetzungen und verwendungen davon
|
CA3150458A1
(en)
|
2019-08-14 |
2021-02-18 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
CN115666589A
(zh)
|
2020-03-19 |
2023-01-31 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
AU2021241682A1
(en)
|
2020-03-27 |
2022-10-13 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
WO2022097157A2
(en)
|
2020-11-09 |
2022-05-12 |
1E Therapeutics, Ltd. |
Catalytic sequence based methods of treating or preventing bacterial infections
|
WO2022130388A2
(en)
|
2020-12-18 |
2022-06-23 |
Yeda Research And Development Co. Ltd. |
Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same
|
KR20230133859A
(ko)
|
2020-12-28 |
2023-09-19 |
1이 테라퓨틱스 엘티디. |
p21 mRNA 표적화 DNA자임
|
EP4267741A2
(de)
|
2020-12-28 |
2023-11-01 |
1E Therapeutics, Ltd. |
P21-mrna-zielbereiche zum silencing
|
CA3207359A1
(en)
|
2021-02-05 |
2022-08-11 |
Cecile Chartier-Courtaud |
Adjuvant therapy for cancer
|
AU2022249318A1
(en)
|
2021-03-31 |
2023-10-12 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
CA3216719A1
(en)
|
2021-05-03 |
2022-11-10 |
Astellas Institute For Regenerative Medicine |
Methods of generating mature corneal endothelial cells
|
EP4337261A2
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation des spleissens von mrna
|
EP4337263A1
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
|
AU2022271873A1
(en)
|
2021-05-10 |
2024-01-04 |
Entrada Therapeutics, Inc. |
Compositions and methods for intracellular therapeutics
|
EP4355875A1
(de)
|
2021-06-14 |
2024-04-24 |
2seventy bio, Inc. |
Verfahren zur aufreinigung einzelsträngiger rna
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
WO2022271955A1
(en)
|
2021-06-23 |
2022-12-29 |
Musc Foundation For Research Development |
Novel targeted shrna nanoparticles for cancer therapy
|
IL310547A
(en)
|
2021-08-05 |
2024-03-01 |
Sanegene Bio Usa Inc |
Alkyl substituted ribose derivatives in the '1 position and methods of use
|
US11912779B2
(en)
|
2021-09-16 |
2024-02-27 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
US20230241224A1
(en)
|
2021-09-22 |
2023-08-03 |
Sanegene Bio Usa Inc. |
2'-alkyl or 3'- alkyl modified ribose derivatives and methods of use
|
US20230227480A1
(en)
|
2021-10-05 |
2023-07-20 |
Sanegene Bio Usa Inc. |
Polyhydroxylated cyclopentane derivatives and methods of use
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
WO2023164464A1
(en)
|
2022-02-22 |
2023-08-31 |
Sanegene Bio Usa Inc. |
5'-modified carbocyclic ribonucleotide derivatives and methods of use
|
WO2024015796A1
(en)
|
2022-07-11 |
2024-01-18 |
Sanegene Bio Usa Inc. |
Optimized 2'- modified ribose derivatives and methods of use
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|